Rendering
| Component: (Network and Table) | 
|---|
| Network | 3120 - Disclosure - Intangible Assets (Tables) (http://www.acorda.com/role/DisclosureIntangibleAssetsTables)  | 
| Table | (Implied) | 
Slicers (applies to each fact value in each table cell)
| Reporting Entity [Axis] | 0001008848 (http://www.sec.gov/CIK) | 
| Intangible Assets | Period [Axis] | 
|---|
2012-01-01 - 2012-12-31  | 
|---|
Intangible Assets  |    | 
Schedule of intangible assets  | 
  
  
| 
 (In thousands)  | 
    | 
 December 31, 
2012  | 
    | 
 December 31, 
2011  | 
    | 
 Estimated 
remaining 
useful lives as of 
December 31, 
2012  | 
    |  
| 
 Zanaflex Capsule patents  | 
    | 
 $  | 
 19,350  | 
    | 
 $  | 
 19,350  | 
    | 
 0 years  | 
    |  
| 
 Zanaflex trade name  | 
    | 
 2,150  | 
    | 
 2,150  | 
    | 
 0 years  | 
    |  
| 
 Ampyra milestones  | 
    | 
 5,750  | 
    | 
 5,750  | 
    | 
 14 years  | 
    |  
| 
 Ampyra CSRO royalty buyout  | 
    | 
 3,000  | 
    | 
 3,000  | 
    | 
 7 years  | 
    |  
| 
 Website development costs  | 
    | 
 5,841  | 
    | 
 4,028  | 
    | 
 3 years  | 
    |  
| 
 Website development costs — in process  | 
    | 
 712  | 
    | 
 42  | 
    | 
 3 years  | 
    |  
| 
    | 
    | 
 36,803  | 
    | 
 34,320  | 
    | 
    | 
    |  
| 
 Less accumulated amortization  | 
    | 
 27,484  | 
    | 
 25,551  | 
    | 
    | 
    |  
| 
    | 
    | 
 $  | 
 9,319  | 
    | 
 $  | 
 8,769  | 
    | 
    | 
    |    
   | 
Schedule of future amortization expense for intangible assets  | 
Estimated future amortization expense for intangible assets subsequent to December 31, 2012 for the next five years is as follows: 
  
| 
 (In thousands)  | 
    | 
    | 
    |  
| 
 2013  | 
    | 
 $  | 
 1,826  | 
    |  
| 
 2014  | 
    | 
 1,573  | 
    |  
| 
 2015  | 
    | 
 1,368  | 
    |  
| 
 2016  | 
    | 
 588  | 
    |  
| 
 2017  | 
    | 
 588  | 
    |  
| 
    | 
    | 
 $  | 
 5,943  | 
    |    
   | 
Estimated future amortization expense for intangible assets subsequent to December 31, 2012 for the next five years is as follows:
 
| 
 (In thousands)  | 
    | 
    | 
    | 
| 
 2013  | 
    | 
 $  | 
 1,826  | 
    | 
| 
 2014  | 
    | 
 1,573  | 
    | 
| 
 2015  | 
    | 
 1,368  | 
    | 
| 
 2016  | 
    | 
 588  | 
    | 
| 
 2017  | 
    | 
 588  | 
    | 
| 
    | 
    | 
 $  | 
 5,943  | 
    | 
 
 
 
| 
 (In thousands)  | 
    | 
 December 31, 
2012  | 
    | 
 December 31, 
2011  | 
    | 
 Estimated 
remaining 
useful lives as of 
December 31, 
2012  | 
    | 
| 
 Zanaflex Capsule patents  | 
    | 
 $  | 
 19,350  | 
    | 
 $  | 
 19,350  | 
    | 
 0 years  | 
    | 
| 
 Zanaflex trade name  | 
    | 
 2,150  | 
    | 
 2,150  | 
    | 
 0 years  | 
    | 
| 
 Ampyra milestones  | 
    | 
 5,750  | 
    | 
 5,750  | 
    | 
 14 years  | 
    | 
| 
 Ampyra CSRO royalty buyout  | 
    | 
 3,000  | 
    | 
 3,000  | 
    | 
 7 years  | 
    | 
| 
 Website development costs  | 
    | 
 5,841  | 
    | 
 4,028  | 
    | 
 3 years  | 
    | 
| 
 Website development costs — in process  | 
    | 
 712  | 
    | 
 42  | 
    | 
 3 years  | 
    | 
| 
    | 
    | 
 36,803  | 
    | 
 34,320  | 
    | 
    | 
    | 
| 
 Less accumulated amortization  | 
    | 
 27,484  | 
    | 
 25,551  | 
    | 
    | 
    | 
| 
    | 
    | 
 $  | 
 9,319  | 
    | 
 $  | 
 8,769  | 
    | 
    | 
    |